Predicting future suicidal events in adolescents using the Concise Health Risk Tracking Self-Report (CHRT-SR).

BACKGROUND

Several self-report rating scales have been developed to assess suicidal ideation, yet most have limited utility in predicting future suicide attempts. This is particularly critical in adolescence, where suicide is the second leading cause of death. This study evaluated the Concise Health Risk Tracking Self-Report (CHRT-SR) as a prospective predictor of suicide attempts and events in high-risk adolescents enrolled in a suicide-prevention intensive outpatient program (IOP).

METHODS

Data were collected by retrospective chart review of adolescents treated in IOP for youth with severe suicidality. At baseline, youth completed the 14-item CHRT-SR (CHRT-SR

RESULTS

Of the 251 adolescents who completed the baseline CHRT-SR

CONCLUSIONS

The CHRT-SR

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Dr. Rush has received consulting fees from Akili, Brain Resource Inc., Compass Inc., Curbstone Consultant LLC, Emmes Corp., Johnson and Johnson (Janssen), Liva-Nova, Mind Linc, Otsuka-US, Sunovion; speaking fees from Liva-Nova; and royalties from Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptoms and its derivatives). He is also named co-inventor on two patents: U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS; and U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. Dr. Emslie has received research/grant from Duke University, Forest Research Institute, and Janssen Research & Development. Dr. Emslie is a consultant for Assurex Health Inc., Lundbeck, Neuronetics Inc., Otsuka, and Pfizer Inc. Dr. Kennard is currently serving on the Board of Trustees for the Jerry M. Lewis, M.D. Mental Health Research Foundation. Dr. Kennard receives royalties from Guilford Press, Inc. Dr. Jha has received research funding from Acadia Pharmaceuticals and Janssen Research & Development, and honoraria for CME presentations from North American Center for Continuing Medical Education and Global Medical Education. Dr. Hughes receives royalties from Guilford Press. Dr. Trivedi has received research funding from NIMH, NIDA, and Patient-Centered Outcomes Research Institute (PCORI), Cancer Prevention Research Institute of Texas (CPRIT); has served as a consultant for Allergan, Alto Neuroscience Inc, Applied Clinical Intelligence LLC, Axsome Therapeutics, Boegringer Ingelheim, Engage Health Media, GreenLight VitalSign6 Inc, Janssen, Lundbeck Research USA, Merck Sharp & Dohme Corp., Navitor Pharmaceutical Inc, Otsuka, Perception Neuroscience, Pharmerit International, SAGE Therapeutics, Signant Health; and has received editorial compensation from American Psychiatric Association (Deputy Editor for American Journal of Psychiatry), Oxford University Press; Dr. Carmody owns stock in Vertex Pharmaceuticals and CRISPR Therapeutics; Ms. Mayes and Drs. Killian, and King, have no financial relationships with commercial interests.